The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
kang gao xue ya yao dui xue zhi de ying xiang
Author(s): 
Pages: 346-348
Year: Issue:  6
Journal: World Clinical Drugs

Keyword:  抗高血压药多噻嗪低密度脂蛋白降压药治疗噻嗪类高血压性心肌病降压药物利尿药洛尔高密度脂蛋白;
Abstract: <正> 高血压是动脉粥样硬化的主要危险因素。高血压病经降压药治疗后,脑血管意外、肾功能衰竭、高血压性心肌病等明显减少,但心肌梗塞发病率未见下降,其原因不明。近来发现,多种抗高血压药可使总胆固醇、甘油三酯增加及/或高密度脂蛋白(HDL)减少,以致心血管危险因素增加。因而,选择降压药物时必须注意其不良作用。利尿药噻嗪类氢氯噻嗪、多噻嗪、环戊氯噻嗪、氯帕胺(Clopamide)、苯氟噻嗪和美夫西特(Mefruside)等,可使总胆固醇、甘油三酯、极低密度脂蛋白(VLDL)、低密度脂蛋白
Related Articles
No related articles found